Published in Women's Health Weekly, December 16th, 2004
According to a study from the United States, "DMPA-SC 104 mg/0.65 mL is a new, low-dose subcutaneous (SC) formulation of Depo-Provera contraceptive injection (150 mg/mL medroxyprogesterone acetate injectable suspension) that provides efficacy, safety and immediacy of onset equivalent to Depo-Provera intramuscular (IM) injection. Two large, open-label, Phase 3 studies assessed the one-year contraceptive efficacy, safety and patient satisfaction with DMPA-SC administered every three months (12-13 weeks)."
"Zero pregnancies were...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly